Global Depression Treatment Industry to 2032 – by Products, Disease, Distribution Channel and Region –


DUBLIN–()–The “Depression Treatment Market” report has been added to from offer.

A recent market study released on the Depression Treatment Market offers an overall industry analysis for 2012-2021 and opportunity assessment for 2022-2032. The report consists of a comprehensive assessment of the most important market dynamics.

By conducting thorough research on the historical and current growth parameters of the Depression Treatment Market, market growth prospects are obtained with utmost accuracy.

The report presents unique and salient factors which may have a huge impact on the development of the depression treatment market during the forecast period. It can help market players to modify their manufacturing and marketing strategies to envision maximum growth of this market in the coming years.

The report provides detailed information about the current and future growth prospects of the Depression Treatment Market in the most comprehensive manner for the better understanding of the readers.

Companies cited

  • Viatris (Mylan Pharmaceuticals Inc.)

  • Sunovian Pharmaceuticals

  • AbbVie Inc. (Allergan Inc.)

  • Jubilant Generics Limited

  • Sanis Health Inc.

  • Abbott Laboratories

  • Aurobindo Pharmacy

  • Pharmaceuticals Torrent

  • Teva Pharmaceuticals

  • Sun pharmaceuticals

  • (Apotex Holdings Inc.) Apotex Corporation

  • Alembic Pharmaceuticals Limited

  • Pfizer Inc.

  • Cardinal Health

  • Hikma Pharmaceuticals

  • Zydus Life Sciences (Cadila)

  • Cipla Ltd

  • Dr. Reddy’s Laboratories

  • Merck & Co.

  • Eli Lily & Co

  • GlaxoSmithKline

  • Takeda Pharmaceuticals

  • BrainsWay Ltd.

  • Nexstim Plc

  • Magstim Ltd.

  • Neuronetics Inc.

  • Salience TMS Neuro Solutions

  • MagVenture

  • MAG & More GmbH

  • Neurosoft Ltd.

Key segments of the depression treatment market

This Depression Treatment Market study offers information divided into four major segments: product, disease, distribution channel, and region.

This report offers comprehensive data and insights on important market dynamics and growth parameters associated with these categories.

By products

  • Drugs

  • Selective serotonin reuptake inhibitors (SSRIs)

  • Citalopram

  • Escitalopram

  • Fluoxetine

  • Fluvoxamine

  • Paroxetine

  • Sertraline

  • Selective norepinephrine reuptake inhibitors (SNRIs)

  • Desvenlafaxine succinate

  • Duloxetine

  • Levomilnacipran

  • Venlafaxine

  • Bupropion

  • Mirtazapine

  • Monoamine oxidase inhibitors (MAOIs)

  • Phenelzine

  • Tranylcypromine

  • Antipsychotics

  • lithium carbonate

  • Aripiprazole

  • Brexipiprazole

  • Quetiapine

  • Trazodone

  • Others

  • TMS devices

  • rTMS devices

  • dTMS devices

By disease

  • Major depression

  • Persistent depressive disorder

  • Bipolar disorder

  • Seasonal Affective Disorder (SAD)

  • Postpartum depression

  • Premenstrual dysphoric disorder (PDD)

  • Situational depression

  • Atypical depression

  • Treatment resistant depression

By distribution channel

  • Hospitals

  • Retail pharmacies

  • Pharmacies

  • e-commerce

  • Specialized clinics


  • North America

  • Latin America

  • Europe

  • East Asia

  • South Asia

  • Oceania

  • Middle East and Africa (MEA)

For more information on this report, visit


Comments are closed.